| __timestamp | Bristol-Myers Squibb Company | Ionis Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 3932000000 | 241751000 |
| Thursday, January 1, 2015 | 3909000000 | 322292000 |
| Friday, January 1, 2016 | 4946000000 | 344320000 |
| Sunday, January 1, 2017 | 6066000000 | 374644000 |
| Monday, January 1, 2018 | 6547000000 | 1820000 |
| Tuesday, January 1, 2019 | 8078000000 | 4000000 |
| Wednesday, January 1, 2020 | 11773000000 | 12000000 |
| Friday, January 1, 2021 | 9940000000 | 11000000 |
| Saturday, January 1, 2022 | 10137000000 | 14000000 |
| Sunday, January 1, 2023 | 10693000000 | 9133000 |
| Monday, January 1, 2024 | 11949000000 | 11215000 |
Unlocking the unknown
In the ever-evolving pharmaceutical industry, understanding cost dynamics is crucial. Bristol-Myers Squibb Company (BMY) and Ionis Pharmaceuticals, Inc. (IONS) present a fascinating contrast in cost of revenue trends from 2014 to 2023. Over this period, BMY's cost of revenue surged by approximately 172%, peaking in 2020 with a notable 11% increase from the previous year. This growth reflects BMY's strategic investments and scaling operations. In contrast, Ionis Pharmaceuticals experienced a more volatile trajectory, with costs fluctuating significantly. Notably, Ionis saw a dramatic drop in 2018, with costs plummeting by over 99% compared to 2017, highlighting potential shifts in operational focus or strategic pivots. These trends underscore the diverse strategies employed by pharmaceutical giants in managing operational costs, offering valuable insights into their financial health and market strategies.
Comparing Cost of Revenue Efficiency: Eli Lilly and Company vs Ionis Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for Johnson & Johnson and Ionis Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Merck & Co., Inc. vs Ionis Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Amgen Inc. vs Bristol-Myers Squibb Company
Cost of Revenue Trends: Bristol-Myers Squibb Company vs Incyte Corporation
Cost of Revenue: Key Insights for Bristol-Myers Squibb Company and Pharming Group N.V.
Comparing Cost of Revenue Efficiency: Incyte Corporation vs Ionis Pharmaceuticals, Inc.
Analyzing Cost of Revenue: Dr. Reddy's Laboratories Limited and Ionis Pharmaceuticals, Inc.
Cost of Revenue Trends: Sarepta Therapeutics, Inc. vs Ionis Pharmaceuticals, Inc.
Cost Insights: Breaking Down Telix Pharmaceuticals Limited and Ionis Pharmaceuticals, Inc.'s Expenses
Cost of Revenue Trends: Ionis Pharmaceuticals, Inc. vs CRISPR Therapeutics AG
Cost of Revenue Trends: Ionis Pharmaceuticals, Inc. vs PTC Therapeutics, Inc.